Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine stops cells from making deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Venetoclax is in a class of medicatio

Trial Details

NCT ID
NCT03874052
Phase
PHASE1
Sponsor
Jennifer Saultz
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Echocardiography Test
  • Punch Biopsy
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Portland, Oregon, United States|45.52345,-122.67621
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Ability to understand and the willingness to sign a written informed consent document
  • Age \>= 18 years at time of informed consent. Persons of all genders and gender identities, and members of all races and ethnic groups will be incl…
  • Morphologically documented relapsed/refractory (R/R) AML or R/R secondary AML (sAML) that has progressed after at least 1 prior therapy for AML
  • Prior treatment with venetoclax and azacitidine is allowed

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →